Genmab AS is a leading, internationally acclaimed biotechnology company founded in 1999, based in Copenhagen, Denmark with subsidiaries in Utrecht, the Netherlands, and Princeton, New Jersey, USA. The company specializes in the creation and development of innovative and differentiated antibody therapeutics for the treatment of cancer. These fall under the category of targeted therapeutics, which work by specifically attacking cancerous cells while minimizing damage to normal cells. This specificity increases the efficacy of treatments while reducing side effects experienced by patients.
Genmab AS's strong R&D capabilities, sound financials, and lucrative partnerships have proven a winning formula in the biotechnology industry, garnering them a listing on the NASDAQ Copenhagen and NASDAQ New York stock exchanges under the ticker symbol GMAB. The company's market capitalization stands at approximately 104.95 billion USD, with shares trading at a high valuation reflecting the promise of its rich pipeline.
The company has developed two approved antibodies, Darzalex (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Genmab AS also has a broad portfolio of promising product candidates. Its products adopt the use of three versatile, proprietary technology platforms: the DuoBody platform for creating bispecific antibodies, the HexaBody platform for generation of hexavalent antibodies, and the HexElect platform for creating bispecific, hexavalent antibodies.
While profits and revenues can be volatile due to the risky nature of drug discovery and development, Genmab’s financial performance tends to fare well, owed largely to milestone revenues and royalties derived from multiple collaborations.
Genmab AS's aspiration is to improve the lives of patients by creating and developing innovative antibody products. Inspired by this purpose, it invests heavily in attracting and retaining a diverse team of passionate and innovative employees committed to achieving this mission. The company operates under a set of values including Integrity, Innovation, Passion, Performance and Collaboration, which they credit for their success.
They are also committed to maintaining a strong culture of corporate responsibility and have stated their dedication to conducting their business sustainably, with a particular focus on minimizing their environmental impact and supporting their local communities. The company has consistently demonstrated an unwavering commitment to their scientific endeavors and corporate responsibility, solidifying their position as a respected leader in their field.